GHK-Cu.

Copper-binding peptides studied in skin, wound, and collagen biology.

Copper is an essential trace metal and a cofactor for enzymes central to connective tissue, including lysyl oxidase, which cross-links collagen and elastin, and superoxide dismutase, which handles reactive oxygen species. Free copper ions are also chemically dangerous, since they catalyse reactions that generate damaging radicals. The body therefore keeps almost no copper unbound, using dedicated transport proteins and small chelating molecules to move it safely between compartments. The tripeptide in this group is one such chelator. Its glycine amino terminus, its histidine imidazole ring, and a deprotonated peptide nitrogen together form a square-planar coordination site for copper in its Cu(II) oxidation state, a geometry confirmed by structural studies. This lets the peptide shuttle copper to and from cells and modulate copper's redox chemistry rather than simply delivering the metal. The peptide occurs naturally in plasma, and its concentration is described as declining with age, which is the observation the whole field is built on. Beyond copper transport, the complex has been reported to stimulate dermal fibroblasts to produce type I and type III collagen, elastin, glycosaminoglycans, and proteoglycans, while simultaneously modulating matrix metalloproteinases and their tissue inhibitors. That combination matters: remodelling requires both building new matrix and controlled breakdown of old matrix, and a molecule that influences both sides is described as a remodelling signal rather than a simple stimulant. Broad effects on gene expression have also been reported in cell studies. A practical constraint dominates real-world use. The peptide is hydrophilic and charged, and the stratum corneum is a lipid barrier designed to exclude exactly that kind of molecule. How much of a topically applied copper peptide reaches the dermal fibroblasts it is supposed to act on is genuinely uncertain and depends heavily on formulation. Copper complexes also have colour and stability characteristics that constrain how they can be formulated. On clinical relevance: this compound is used as a cosmetic ingredient rather than as an approved drug, and cosmetic ingredients are not required to demonstrate clinical efficacy. The cell-level biology is reasonably well characterised. Controlled human trials showing meaningful improvement in skin structure are limited in number and size, and much of the supporting literature comes from investigators closely associated with the ingredient.

Signalling that builds, protects, or remodels the structural scaffold around cells.

The extracellular matrix is the scaffold cells live in: collagens for tensile strength, elastin for recoil, fibronectin and laminin for adhesion, and proteoglycans and glycosaminoglycans that hold water and govern how signalling molecules diffuse. It is not inert. It is continuously synthesised and degraded, with matrix metalloproteinases doing the cutting and tissue inhibitors of metalloproteinases restraining them. Ageing, ultraviolet exposure, and chronic inflammation shift this balance toward net loss, which is the structural basis of skin ageing and of several degenerative conditions. One route into this system is the matrikine concept. When collagen is degraded, specific short fragments are liberated, and these fragments appear to act as feedback signals telling fibroblasts to make more matrix. A pentapeptide from the carboxy-terminal propeptide of type I collagen is the best-known example, and in cultured dermal fibroblasts it has been reported to stimulate production of type I and type III collagen, fibronectin, and glycosaminoglycans. Because the peptide itself is hydrophilic, a fatty palmitoyl tail is attached purely to make it lipophilic enough to cross the stratum corneum. That tail has no pharmacological role of its own, a detail frequently misrepresented. A second route works through copper coordination, supplying a cofactor for the enzymes that cross-link collagen and elastin while also modulating matrix metalloproteinase activity, which affects both the building and the breaking side of remodelling. A third acts protectively rather than synthetically. A semi-synthetic sulfated polysaccharide with a heparin-like structure behaves as an exogenous glycosaminoglycan, proposed to adhere to and replenish the protective glycosaminoglycan layer lining the bladder urothelium so that irritating urinary solutes reach underlying nerves less readily. Its structure also gives it mild anticoagulant activity and the ability to bind growth factors and inhibit heparanase, which is the basis for separate interest in joint and inflammatory contexts. Honesty about evidence: the matrikine peptides are cosmetic ingredients, not drugs, and cosmetic ingredients need not demonstrate clinical efficacy. Fibroblast responses in culture are well documented; controlled human trials showing meaningful structural change in skin are far more limited. The bladder agent is an approved prescription medicine, but its own label states that the precise mechanism is unknown, and long-term use has been associated with a distinctive retinal disorder that requires ophthalmological monitoring.

Topical/cosmetic skin and collagen effects have some support; 'reversal' overstates it.

Hair claims are not well established in controlled human studies.

Systemic longevity claims go well beyond the topical/cosmetic evidence.